|Bid||70.2500 x 1100|
|Ask||70.2600 x 300|
|Day's Range||69.8400 - 71.3700|
|52 Week Range||63.7600 - 88.8500|
|PE Ratio (TTM)||7.45|
|Dividend & Yield||2.08 (2.95%)|
|1y Target Est||N/A|
The sleeping giant has awakened. Which makes it a perfect time for an analyst to start Gilead Sciences' (GILD) stock with a buy rating. It centers on Gilead's valuation, a thesis that "is not new, but is also not necessarily wrong." They explain: While we fully expect Gilead to ultimately (and yes, eventually) pursue and execute on a business development strategy that should prove transformative (and hence render our outlook on the existing business less relevant) we believe concerns around the stock being a "value trap" for investors will soon come to pass.
The stock has been on fire.
Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...